Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-21 EST			5-day change	1st Jan Change
32.98 ^USD	+0.09%		-3.00%	-8.08%

01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI
01-08	Indivior Expects Up to $1.20 Billion in 2026 Net Revenue	MT

HC Wainwright Initiates Indivior at Buy With $28 Price Target

Published on 08/06/2025 at 07:45 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Indivior PLC

01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI
01-08	Indivior Expects Up to $1.20 Billion in 2026 Net Revenue	MT
01-08	(INDV) Indivior Expects 2026 Revenue Range $1.13B - $1.2B, vs. FactSet Est of $1.19B	MT
12-22	Indivior Joins S&P SmallCap 600 Index	MT
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 1000	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Pharmaceuticals Select Industry Index	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600 Health Care	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Composite 1500	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600	CI
11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI
25-10-30	Sector Update: Health Care Stocks Rise Late Afternoon	MT
25-10-30	Indivior PLC, Q3 2025 Earnings Call, Oct 30, 2025
25-10-30	Top Midday Gainers	MT
25-10-30	Indivior PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Indivior Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Outlook Raised - Shares Up Pre-Bell	MT
25-10-30	Indivior PLC Raises Earnings Guidance for the Year 2025	CI
25-10-30	Earnings Flash (INDV) Indivior PLC Reports Q3 Revenue $314.0M, vs. FactSet Est of $261.9M	MT
25-10-30	Earnings Flash (INDV) Indivior PLC Posts Q3 Adjusted EPS $0.72 per Share, vs. FactSet Est of $0.41	MT
25-10-15	Indivior Says Rapid Sublocade Induction Improves Retention in Opioid Use Disorder Trial	MT
25-10-15	Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open	CI
25-10-01	UK's Indivior to re-domicile to US after listing move	RE
25-10-01	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation	CI
25-09-21	Indivior PLC(NasdaqGS:INDV) added to S&P TMI Index	CI
25-09-08	Indivior PLC Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 09:15 AM

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company